2022
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
Roque DM, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader JC, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD. Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British Journal Of Cancer 2022, 126: 1695-1703. PMID: 35149854, PMCID: PMC8853032, DOI: 10.1038/s41416-022-01717-6.Peer-Reviewed Original ResearchConceptsPrimary peritoneal cancerPeritoneal cancerPredictive biomarkersDay 1Taxane-resistant ovarian cancerPhase II trialM2 days 1Bevacizumab 10Evaluable patientsPrior bevacizumabWeekly ixabepiloneII trialPrimary endpointSecondary endpointsRefractory statusTUBB3 expressionPrior receiptSubgroup analysisClinical trialsOvarian cancerIxabepilonePFSCancerBevacizumabPatients
2021
Health-related quality of life (HRQoL) in advanced endometrial cancer (aEC) patients (pts) treated with lenvatinib plus pembrolizumab or treatment of physician’s choice (TPC).
Lorusso D, Colombo N, Herraez A, Santin A, Colomba E, Miller D, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Kim Y, McCormack M, Bird S, Prabhu V, Nguyen A, Zhao Q, Dutta L, Makker V. Health-related quality of life (HRQoL) in advanced endometrial cancer (aEC) patients (pts) treated with lenvatinib plus pembrolizumab or treatment of physician’s choice (TPC). Journal Of Clinical Oncology 2021, 39: 5570-5570. DOI: 10.1200/jco.2021.39.15_suppl.5570.Peer-Reviewed Original ResearchGlobal health statusEORTC QLQ-C30QLQ-C30QOL scoresEORTC QLQ-C30 global health statusDay 1QLQ-C30 global health statusFavorable benefit/risk profileCompliance rateWk 12Advanced endometrial cancer patientsCycle 1 day 1GHS/QoL scoresPlatinum-based systemic therapyBenefit/risk profileEndometrial cancer patientsHealth-related qualityStandard treatment approachPlatinum-based therapyTime of discontinuationBetween-group differencesWorse symptom severityGHS/HRQOL endpointsQd po
2016
Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma.
Abu-Khalaf MM, Raza MA, Hatzis C, Wang H, Lin K, Higgins S, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Santin AD, Schwartz PE. Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma. European Journal Of Gynaecological Oncology 2016, 37: 199-203. PMID: 27172745.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnemiaAntineoplastic Combined Chemotherapy ProtocolsBrachytherapyCarcinosarcomaChemoradiotherapyCisplatinDisease-Free SurvivalFemaleHumansIfosfamideMesnaMiddle AgedNeoplasm StagingNeutropeniaProtective AgentsRetrospective StudiesTreatment OutcomeUterine NeoplasmsConceptsVaginal cuff brachytherapyProgression-free survivalFirst-line treatmentOverall survivalUterine carcinosarcomaStage ILine treatmentStage IIIDay 1Anemia grade 1Most common toxicitiesNeutropenia grade 3Cycles of cisplatinMedian overall survivalStage IV diseaseCommon toxicitiesMedian followTreatment discontinuationFree survivalPatient withdrawalCombination cisplatinDose modificationMedian ageRetrospective studyGrade 3
2014
Phase I Clinical Trial of the Mammalian Target of Rapamycin Inhibitor Everolimus in Combination With Oral Topotecan for Recurrent and Advanced Endometrial Cancer
Acevedo-Gadea C, Santin AD, Higgins SA, Urva S, Ratner E, Silasi DA, Azodi M, Rutherford T, Schwartz PE, Abu-Khalaf MM. Phase I Clinical Trial of the Mammalian Target of Rapamycin Inhibitor Everolimus in Combination With Oral Topotecan for Recurrent and Advanced Endometrial Cancer. International Journal Of Gynecological Cancer 2014, 24: 528-533. PMID: 24557436, DOI: 10.1097/igc.0000000000000085.Peer-Reviewed Original ResearchConceptsOral topotecanEndometrial cancerDay 1Pelvic external beam radiation therapyMammalian targetExternal beam radiation therapyPhase I clinical trialRecurrent endometrial cancerAdvanced endometrial cancerDose-limiting toxicityEfficacy of topotecanRapamycin inhibitor everolimusBeam radiation therapyOral everolimusStable diseaseVaginal brachytherapyMedian ageRapamycin inhibitorsInhibitor everolimusPreclinical dataClinical trialsMedian numberPharmacokinetic assessmentRadiation therapyEverolimus